Sponsor
Summit Therapeutics
Clinical research sponsor
Clinical trials
13 shownClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · lead sponsor · 2025-02-27
RECRUITINGClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · lead sponsor · 2023-10-26
RECRUITINGPhase III Study of AK112 for NSCLC PatientsNCT06396065 · lead sponsor · 2023-05-04
ACTIVE_NOT_RECRUITINGA Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerNCT07619339 · collaborator · 2026-05-27
RECRUITINGIvonescimab Alone And With Carboplatin/Pemetrexed For NSCLCNCT07405190 · collaborator · 2026-05-01
RECRUITINGA Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung CancerNCT07535463 · collaborator · 2026-04-10
RECRUITINGA Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerNCT07535437 · collaborator · 2026-04-09
RECRUITINGPhase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerNCT07057791 · collaborator · 2026-03-30
RECRUITINGStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338 · collaborator · 2026-01-30
RECRUITINGPhase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast CancerNCT07017673 · collaborator · 2025-07-25
RECRUITINGEvaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyNCT06840834 · collaborator · 2025-06-30
RECRUITINGPhase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell CarcinomaNCT06567314 · collaborator · 2024-12-02
RECRUITINGPhase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain MetsNCT07234877 · collaborator · 2026-11-01
NOT_YET_RECRUITINGSponsor roles
collaborator10
lead sponsor3
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.